Robert Allison, MD
Internal Medicine · Pierre, SDNPI 1154393742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 425 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 425 payments — averaging $14.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$810
- Amgen$751
- Novo Nordisk$705
- Pfizer$648
- E.r. Squibb & Sons, L.L.C.$489
- Boehringer Ingelheim$360
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,999100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 52 | $810 |
| Amgen | 55 | $751 |
| Novo Nordisk | 46 | $705 |
| Pfizer | 51 | $648 |
| E.r. Squibb & Sons, L.L.C. | 38 | $489 |
| Boehringer Ingelheim | 29 | $360 |
| Astellas Pharma US Inc | 20 | $298 |
| Merck | 27 | $229 |
| Daiichi Sankyo Inc. | 10 | $216 |
| Johnson & Johnson | 34 | $212 |
| AstraZeneca | 7 | $196 |
| Medtronic | 4 | $175 |
| Novartis | 7 | $131 |
| GSK | 8 | $119 |
| Exact Sciences | 7 | $118 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $99 |
| Vertex | 6 | $95 |
| AbbVie | 4 | $81 |
| Grifols USA, LLC | 3 | $51 |
| Philips North America LLC | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Boston Scientific | 1 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Bayer | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Axonics, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Solventum Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$112
- FARXIGA$112
- BEVESPI AEROSPHERE$112
How this compares
$5,999 in reported general payments places this provider in the 95th percentile of 178 internal medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 176 | $144,359 |
| JardianceEmpagliflozin | 94 | $82,957 |
| OzempicSemaglutide | 47 | $58,582 |
| TrulicityDulaglutide | 51 | $53,886 |
| NuplazidPimavanserin Tartrate | 13 | $32,490 |
| RybelsusSemaglutide | 24 | $30,783 |
| MounjaroTirzepatide | 20 | $23,805 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $18,808 |
| JanuviaSitagliptin Phosphate | 13 | $16,901 |
| EntrestoSacubitril/Valsartan | 13 | $15,367 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,782 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $10,982 |
| FarxigaDapagliflozin Propanediol | 11 | $10,228 |
| TrintellixVortioxetine Hydrobromide | 19 | $9,208 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $648 | $144,359176 claims |
| Novo NordiskOzempic, Rybelsus | $705 | $89,36571 claims |
| Boehringer IngelheimJardiance | $360 | $82,95794 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $810 | $77,69171 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $119 | $23,82836 claims |
| MerckJanuvia | $229 | $16,90113 claims |
| NovartisEntresto | $131 | $15,36713 claims |
| AstraZenecaFarxiga | $196 | $10,22811 claims |
| AbbVieSynthroid | $81 | $2,32245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 178 internal medicine providers in South Dakota.
Other internal medicine in Pierre
- Darrell PlumagePierre$6K
- Philip MeyerPierre$289
- Jennifer MayRapid City$52K
- Richard BeasleyRapid City$25K
- Issam TurkRapid City$14K
- Janell PowellSioux Falls$7K
- Maaz BadshahSioux Falls$6K
- Travis HendersonMobridge$6K
- Wendy VetterSioux Falls$5K
- Josh HendersonMobridge$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.